Integrating Multiple Outcomes of First-Line Immunotherapy-Based Regimens for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials - PubMed
3 hours ago
- #network-meta-analysis
- #hepatocellular-carcinoma
- #immunotherapy
- This network meta-analysis of 12 phase III RCTs (7,908 patients) evaluates first-line immunotherapy-based regimens for advanced hepatocellular carcinoma (HCC).
- Sintilimab plus IBI305 showed the highest probability for best overall survival (OS) benefit in the overall population.
- Finotonlimab plus bevacizumab ranked highest for improving OS in younger patients and those with HBV-related HCC, and for best progression-free survival (PFS) overall.
- When integrating efficacy, safety, and quality-of-life outcomes, finotonlimab plus bevacizumab and atezolizumab plus bevacizumab demonstrated the best overall performance.
- Bevacizumab-based immunotherapy combinations offer a favorable benefit-risk balance, with finotonlimab plus bevacizumab highlighted for its translational potential.